Xylyx Bio
Xylyx Bio is a private regenerative medicine company developing bioengineered human organ grafts via xenogeneic cross-circulation and tissue-specific dECM kits and peptide ingredients, serving pharmaceutical researchers, transplant medicine programs, and premium skincare consumers through its Sweet Chemistry subsidiary.
- Company typePrivate
- Founded2016
- HeadquartersBrooklyn, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Xylyx Bio does
Xylyx Bio, Inc. is a privately held regenerative medicine company founded in 2016 and headquartered in Brooklyn, New York. The company operates two technology platforms: (1) the Inspirex™ platform, which uses xenogeneic cross-circulation (XC) with a porcine bioreactor to rehabilitate discarded donor organs into functional, anatomically compatible whole organ grafts (Lung, Liver, Kidney, Heart programs) for clinical transplantation; and (2) the Matrix Biotechnologies platform, which produces tissue-specific decellularized extracellular matrix (dECM) products under the InMatrico® and TissueSpec® brands — coating and hydrogel kits for bone, heart, intestine, kidney, liver, lung, skin, fibrotic and metastatic disease models — together with ExMatrico®/Matrikynes® bioactive peptide ingredients for regenerative applications.
The company monetizes through three streams: direct e-commerce and international distributor sales of InMatrico/TissueSpec dECM kits and assays to academic and pharmaceutical researchers across more than 30 countries; the 2023-launched wholly-owned consumer skincare subsidiary Sweet Chemistry, which sells Matrikynes-based peptide products at $148–$170 per unit through premium retail (Violet Grey) with broader distribution in pursuit; and non-dilutive grant funding from the NIH (SBIR awards exceeding $6.7M across NIDDK, NCI, and NHLBI between 2021 and 2024) and private foundations ($1.125M in 2025). The Inspirex organ graft program is pre-revenue, with lung and liver at the most advanced preclinical stages. Research collaborations with Stanford Medicine, Columbia University Irving Medical Center, and Stevens Institute of Technology support platform development, and an exclusive license from Vanderbilt University covers donor organ rehabilitation technology.
Management is led by CEO Andrea Nye (formerly Managing Director of Columbia BiomedX), CSO and Co-Founder Dr. John O'Neill (an inventor on multiple patents covering ex vivo organ support and ECM biomaterials), and Board Chair/Interim CFO Anthony Curro (35+ years of life sciences leadership including Guidant/Boston Scientific). Co-Founder Gordana Vunjak-Novakovic of Columbia University serves as Board Chair Emeritus.
Xylyx Bio firmographics
Firmographics- Name
- Xylyx Bio
- Legal name
- Xylyx Bio, Inc.
- Website
- https://xylyxbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Xylyx Bio is a private regenerative medicine company developing bioengineered human organ grafts via xenogeneic cross-circulation and tissue-specific dECM kits and peptide ingredients, serving pharmaceutical researchers, transplant medicine programs, and premium skincare consumers through its Sweet Chemistry subsidiary.
- Ownership category
- akta.pro rank
Where Xylyx Bio is headquartered
LocationHeadquarters
- HQ city
- Brooklyn
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Xylyx Bio business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- dECM Kits and Assays Sales: Sale of InMatrico TissueSpec dECM kits and assays for disease modeling, drug testing, and research applications. Products include coating kits, hydrogel kits, and specialty assays (Human IPF Assays, Human NASH Assays) sold directly through e-commerce shop and international distributor network.
- ExMatrico/Matrikynes Peptide Sales: Sale of Matrikynes bioactive peptide ingredients and finished skincare products through Sweet Chemistry brand. Products priced from $148 to $170, distributed via retail (Violet Grey) and pursuing additional retail partnerships.
- Bioengineered Organ Grafts (Inspirex): Future revenue from bioengineered human organ grafts (Inspirex Lung, Liver, Kidney, Heart) for clinical transplantation. Currently in development with lung and liver in preclinical/prototype stages, kidney and heart in early development.
- NIH SBIR Grant Funding: Non-dilutive grant funding from NIH Small Business Innovation Research (SBIR) program supporting platform development. Received $2.45M from NIDDK for liver fibrosis drug testing (2024), $2.26M from NCI for metastatic breast cancer modeling (2024), $2.2M from NHLBI fast-track grant (2021).
- Licensing and Technology Transfer: Revenue from exclusive license agreements including Vanderbilt University donor organ rehabilitation technology. Also involves institutional laboratory collaborations with Stanford, Columbia, and Stevens Institute.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Sweet Chemistry peptide skincare products |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Xylyx Bio product offering
Product offeringCore offering
Xylyx Bio develops and sells tissue-specific decellularized extracellular matrix (dECM) kits and assays under its InMatrico brand for disease modeling, translational research, and drug testing by pharmaceutical and academic researchers. The company is also developing bioengineered human whole organ grafts (Inspirex Lung, Liver, Kidney, Heart) via its proprietary XC xenogeneic cross-circulation platform for clinical transplantation, and sells Matrikynes bioactive peptides via its Sweet Chemistry consumer skincare brand.
Product overview
Xylyx Bio operates two main divisions: (1) The Inspirex™ Platform for bioengineered organ transplantation, including Inspirex™ Lung, Inspirex™ Liver, and pipeline programs for Inspirex™ Kidney and Inspirex™ Heart, utilizing the XC™ Platform with xenogeneic cross-circulation technology; and (2) Matrix Biotechnologies offering InMatrico® dECM Kits and Assays including TissueSpec® products for Bone, Heart, Liver, Lung, Kidney, Skin, and fibrotic disease models, plus ExMatrico® Peptides (Matrikynes®) for tissue regeneration. Sweet Chemistry is a consumer sub-brand leveraging Matrikynes® for skincare.
Differentiator
Problem solved
Functional benefit
Brands
- InMatrico: Decellularized extracellular matrix (dECM) kits and assays for physiologically relevant disease modeling, translational research, and therapeutic development
- ExMatrico
- Matrikynes
- Inspirex
- TissueSpec
- Sweet Chemistry
- XC Platform
Products and services
- TissueSpec dECM Kits Ready-to-use tissue-specific decellularized extracellular matrix (dECM) coating and hydrogel kits, available for Bone, Heart, Intestine, Kidney, Liver, Lung, Skin, Liver Fibrotic, Lung Fibrotic, and Multi-Organ Metastasis applications. Used by pharmaceutical and academic researchers for physiologically relevant disease modeling and drug testing.
- Human IPF Assays Cell-based assays for studying idiopathic pulmonary fibrosis (IPF) using tissue-specific dECM. Used by pharmaceutical researchers and academic labs investigating fibrotic lung disease mechanisms and drug candidates.
- Human NASH Assays Cell-based assays for studying non-alcoholic steatohepatitis (NASH) using tissue-specific dECM. Used by pharmaceutical researchers and academic labs investigating liver fibrosis and metabolic disease mechanisms and drug candidates.
- ExMatrico Peptides (Matrikynes) Proprietary combinations of bioactive matrikine peptides that activate pro-regenerative mechanisms to modulate inflammation, reverse tissue damage, and accelerate cellular renewal. Marketed as regenerative peptide ingredients supporting tissue repair and cellular renewal signaling pathways.
- Sweet Chemistry Skincare Products Wholly-owned consumer skincare sub-brand of Xylyx Bio using Matrikynes peptide technology. Four products on the market priced from $148 to $170, distributed through premium retail (Violet Grey) and targeting improvements in barrier function, skin density, hydration, hyperpigmentation, and wrinkles.
Quantifiable outcome
- Matrikynes significantly increases skin density and dermal thickness, restoring lost collagen in just 4 weeks
- +1 more outcomes
Companies that use Xylyx Bio
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Xylyx Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Xylyx Bio partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- Vanderbilt UniversitycoreXylyx Bio announced exclusive license agreement with Vanderbilt University for donor organ rehabilitation technology. This licensing partnership provides access to key technology for the company's organ rehabilitation and bioengineering programs.
- Stanford MedicinecoreOrgan Recovery and Bioengineering Laboratory collaboration with Principal Investigator Brandon Guenthart, MD, Department of Cardiothoracic Surgery. Focus on heart and lung transplantation research using XC Platform.
- Columbia University Irving Medical CentercoreLaboratory for Stem Cells and Tissue Engineering collaboration with Principal Investigator Gordana Vunjak-Novakovic, PhD, Departments of Biomedical Engineering and Medicine. Vunjak-Novakovic serves as Board Chair Emeritus and Co-Founder of Xylyx Bio.
- Stevens Institute of TechnologycoreTranslational Lung Bioengineering Laboratory collaboration with Principal Investigator Jinho Kim, PhD, Department of Biomedical Engineering. Supports lung bioengineering research programs.
- Alec BatisminorPartnered with Alec Batis to launch Sweet Chemistry, an evidence-based regenerative skincare brand using Matrikynes peptide technology. Products retail at Violet Grey with expansion plans.
- TebubiominorEU-Germany distributor for InMatrico TissueSpec dECM kits and assays.
- PELO BiotechminorEU-Germany and EU-Switzerland distributor for InMatrico products.
- FROGGA BiominorCanada distributor for InMatrico TissueSpec dECM products.
- Twin HelixminorEU-wide distributor covering Netherlands, Lithuania, Belgium, Italy and other European countries for InMatrico products.
- FujifilmminorJapan distributor for InMatrico TissueSpec dECM kits.
- Kim & FriendsminorSouth Korea distributor for InMatrico products.
- Afirmus BiosourceminorSingapore distributor for InMatrico TissueSpec dECM kits.
- RhetoricminorIndia distributor for InMatrico products.
- Bio MaxminorMalaysia distributor for InMatrico TissueSpec dECM products.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Xylyx Bio competitors and assessment
Company assessmentEmerging players
- eGenesis: eGenesis is developing gene-edited pig organs for human xenotransplantation, addressing the same organ shortage problem as Xylyx Bio's Inspirex program. Both companies use cross-species biology to expand transplantable organ supply, though eGenesis focuses on whole pig organ transplantation while Xylyx uses porcine bioreactors to rehabilitate human organs.
- CN Bio Innovations: CN Bio develops organ-on-chip and microphysiological systems for preclinical drug testing. Comparable to Xylyx Bio's InMatrico platform in the in vitro disease modeling space — both aim to improve drug development predictive accuracy using more physiologically relevant human tissue models than conventional 2D culture.
Direct peers
- Organovo Holdings: Organovo pioneered 3D bioprinting of human tissue for research and potential therapeutic use. Both companies operate in tissue engineering and regenerative medicine, focused on producing functional human tissue constructs for research and eventual transplantation applications.
- MiMedx Group: MiMedx develops and commercializes placental and amniotic membrane-derived dECM products (EpiFix, AmnioFix) for wound healing and surgical recovery. Directly comparable to Xylyx Bio's InMatrico/TissueSpec dECM platform — both companies commercialize tissue-specific decellularized extracellular matrix products for regenerative medicine applications.
- United Therapeutics: Through its Lung Biotechnology PBC subsidiary, United Therapeutics is developing xeno-transplanted and bioengineered lungs for end-stage pulmonary disease — directly competing with Xylyx Bio's Inspirex Lung program. United Therapeutics also pursues regenerative organ manufacturing at industrial scale, comparable in target indication (organ shortage) though with vastly more resources.
- MatTek Corporation (a CellSystems company): MatTek produces in vitro human tissue models (EpiDerm, EpiOcular, MelanoDerm) used for drug testing, disease modeling, and consumer product safety testing. Directly comparable to Xylyx Bio's InMatrico dECM disease modeling kits — both provide physiologically relevant human tissue substrates for drug development and research.
- Humacyte: Humacyte bioengineers human blood vessels and tissues for regenerative medicine and transplantation. Comparable to Xylyx Bio's Inspirex organ platform in approach — both aim to manufacture implantable human tissues/organs using regenerative bioengineering — though Humacyte is more advanced clinically (Phase 3 programs).
Broad incumbents
- Corning Life Sciences: Corning Life Sciences sells Matrigel basement membrane matrix — the dominant ECM product for cell culture and tissue research. Comparable to Xylyx Bio's TissueSpec dECM kits in customer base (pharma/biotech researchers) and application area, though Corning offers a broader portfolio of life science tools rather than specializing in tissue-specific regenerative ECM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Xylyx Bio social profiles
Digital presenceXylyx Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xylyx Bio leadership team
Management profileNumber of profiles
Profiles5 records
Xylyx Bio subsidiaries and ownership
Company hierarchySubsidiaries1 record
Xylyx Bio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xylyx Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xylyx Bio
What does Xylyx Bio do?
Xylyx Bio develops and sells tissue-specific decellularized extracellular matrix (dECM) kits and assays under its InMatrico brand for disease modeling, translational research, and drug testing by pharmaceutical and academic researchers. The company is also developing bioengineered human whole organ grafts (Inspirex Lung, Liver, Kidney, Heart) via its proprietary XC xenogeneic cross-circulation platform for clinical transplantation, and sells Matrikynes bioactive peptides via its Sweet Chemistry consumer skincare brand.
Is Xylyx Bio a public or private company?
Xylyx Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Xylyx Bio founded?
Xylyx Bio was founded in 2016. It employs 1 to 10 people.
Where is Xylyx Bio based?
Xylyx Bio is headquartered in Brooklyn, United States, in the North America region.
How does Xylyx Bio make money?
Five revenue lines are on record. dECM Kits and Assays Sales are the primary driver. The others are exMatrico/Matrikynes Peptide Sales, bioengineered Organ Grafts (Inspirex), NIH SBIR Grant Funding and licensing and Technology Transfer.
Who are Xylyx Bio's main competitors?
Emerging players on record are eGenesis and CN Bio Innovations. Direct peers are Organovo Holdings, MiMedx Group, United Therapeutics, MatTek Corporation (a CellSystems company) and Humacyte. Corning Life Sciences is listed as a broad incumbent.
Does Xylyx Bio have an API?
No public API is recorded for Xylyx Bio.